Romatolojik Hastalıklarda Laboratuvar Testleri
Özet
Romatizmal hastalıkların tanı, tedavi takibi ve sınıflandırılmasında laboratuvar testleri kritik bir rol oynamaktadır. Bu testlerin etkin yönetimi için yanlış pozitiflik ve yanlış negatiflik oranlarının bilinmesi, sağlıklı popülasyondaki prevalansının dikkate alınması hayati önem taşır. Tam kan sayımı ve akut faz reaktanları (ESR ve CRP), hastalık aktivitesinin değerlendirilmesinde ve immünosupresif ilaçların kemik iliği baskılanması gibi toksik yan etkilerinin izlenmesinde yaygın olarak kullanılır. Benzer şekilde, antiromatizmal ilaçların potansiyel organ hasarlarını önlemek amacıyla tedavi öncesinde ve sürecinde karaciğer (ALT, AST) ve böbrek fonksiyon testleri (kreatinin, GFR) düzenli olarak istenmelidir. Serolojik incelemelerde öne çıkan otoantikorlardan Romatoid Faktör (RF) ve anti-sitrülin peptid antikorları (ACPA) romatoid artrit tanısında; antinükleer antikorlar (ANA), anti-dsDNA ve anti-Sm ise sistemik lupus eritematozus (SLE) teşhisinde yüksek spesifite sağlar. Ayrıca nekrotizan vaskülitlerde ANCA, antifosfolipid sendromunda prokoagülan antikorlar ve lupus nefriti takibinde kompleman (C3, C4) seviyeleri belirleyicidir. Sonuç olarak, ölçüm hatası riskine karşı klinik bulgularla uyuşmayan test sonuçları mutlaka tekrarlanmalı, tanı her zaman kapsamlı bir klinik değerlendirmeyle desteklenmelidir.
Laboratory tests play a critical role in the diagnosis, treatment monitoring, and classification of rheumatic diseases. For effective management, understanding false-positive and false-negative rates and considering prevalence in the healthy population is vital. Complete blood count and acute phase reactants (ESR and CRP) are widely used to assess disease activity and monitor toxic side effects, such as bone marrow suppression caused by immunosuppressive drugs. Similarly, liver (ALT, AST) and renal function tests (creatinine, GFR) must be requested before and during treatment to prevent potential organ damage from antirheumatic drugs. Among the autoantibodies prominent in serological examinations, Rheumatoid Factor (RF) and anti-citrullinated peptide antibodies (ACPA) provide high specificity in rheumatoid arthritis, while antinuclear antibodies (ANA), anti-dsDNA, and anti-Sm are essential for systemic lupus erythematosus (SLE) diagnosis. Additionally, ANCA in necrotizing vasculitis, procoagulant antibodies in antiphospholipid syndrome, and complement levels (C3, C4) in lupus nephritis follow-up are highly determinant. In conclusion, due to the risk of measurement error, test results that do not correlate with clinical signs should be repeated, and diagnosis must always be supported by a comprehensive clinical evaluation.
Referanslar
Reid MC, Lane DA, Feinstein AR. Academic calculations versus clinical judgments: practicing physicians’ use of quantitative measures of test accuracy. Am J Med; 1998;104: 374-380.
Pincus T. A pragmatic approach to cost-effective use of laboratory tests and imaging procedures in patients with musculoskeletal symptoms. Prim Care; 1993;20795-814.
Pincus T. Laboratory tests in rheumatic disease. In: Klippel JH, Dieppe PA, eds. Rheumatology. 2nd ed. London: Mosby International; 1997: 10.1-10.8.
Yazici Y, Erkan D, Paget SA. Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events. Arthritis Rheum; 2003;48: 2769-2772.
Mahabir VK, Ross C, Popovic S, et al. A blinded study of bone marrow examinations in patients with primary immune thrombocytopenia. Eur J Haematol; 2013;90:v121-126.
Yazici Y, Erkan D, Paget SA. Monitoring for methotrexate hepatic toxicity in rheumatoid arthritis patients: is it time to update the guidelines? J Rheumatol; 2002;29: 1586-1589.
Yazici Y, Sokka T, Kautiainen H, et al. Long-term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely due to laboratory abnormalities. Ann Rheum Dis; 2005;64: 207-211.
Yazici Y, Erkan D, Harrison MJ, et al. Methotrexate use in rheumatoid arthritis is associated with few clinically significant liver function test abnormalities. Clin Exp Rheumatol; 2005;23: 517-520.
Zerwekh JE. Blood biomarkers of vitamin D status. Am J Clin Nutr; 2008;87: S1087-S1091.
Gabay C, Kushner I. Acute phase proteins and other systemic responses to inflammation. N Engl J Med; 1999;340: 448-454.
Rood MJ, van Laar JM, de Schepper AM, et al. The Milwaukee shoulder/knee syndrome. J Clin Rheumatol; 2008;14: 249-250.
van de Stadt RJ, van de Voorde-Vissers E, Feltkamp-Vroom TM. Metabolic and secretory properties of peripheral and synovial granulocytes in rheumatoid arthritis. Arthritis Rheum; 1980;23: 17-23.
Davis MJ, Denton J, Freemont AJ, et al. Comparison of serial synovial fluid cytology in rheumatoid arthritis: delineation of subgroups with prognostic implications. Ann Rheum Dis; 1988;47: 559-562.
Andersson AK, Li C, Brennan FM. Recent developments in the immunobiology of rheumatoid arthritis. Arthritis Res Ther; 2008;10(2): 204.
Jones ST, Denton J, Holt PJ, et al. Possible clearance of effete polymorphonuclear leucocytes from synovial fluid by cytophagocytic mononuclear cells: implications for pathogenesis and chronicity in inflammatory arthritis. Ann Rheum Dis; 1993; 52:121-126.
Freemont AJ, Denton J. The disease distribution of synovial fluid mast cells and cytophagocytic mononuclear cells in inflammatory arthritis. Ann Rheum Dis; 1985;44: 312-315.
Bresnihan B. Are synovial biopsies of diagnostic value? Arthritis Res Ther; 2003;5: 271-278.
Johnson JS, Freemont AJ. A 10 year retrospective comparison of the diagnostic usefulness of synovial fluid and synovial biopsy examination. J Clin Pathol; 2001;54: 605-607.
